Qualitative And Quantitative Evaluation Of Human Dental Enamel After Bracket Debonding: A Noncontact Three-dimensional Optical Profilometry Analysis

Objectives: The aim of this study was to undertake a qualitative and quantitative evaluation of changes on enamel surfaces after debonding of brackets followed by finishing procedures, using a high-resolution three-dimensional optical profiler and to investigate the accuracy of the technique. Materials and methods: The labial surfaces of 36 extracted upper central incisors were examined. Before bonding, the enamel surfaces were subjected to profilometry, recording four amplitude parameters. Brackets were then bonded using two types of light-cured orthodontic adhesive: composite resin and resin-modified glass ionomer cement. Finishing was performed by three different methods: pumice on a rubber cup, fine and ultrafine aluminum oxide discs, and microfine diamond cups followed by silicon carbide brushes. The samples were subsequently re-analyzed by profilometry. Results: Wilcoxon signed-rank test, Kruskal-Wallis test (p < 0.05) and a posteriori Mann-Whitney U test with Bonferroni correction (p < 0.0167) revealed a significant reduction of enamel roughness when diamond cups followed by silicon carbide brushes were used to finish surfaces that had remnants of resin-modified glass ionomer adhesive and when pumice was used to finish surfaces that had traces of composite resin. Enamel loss was minimal. Conclusions: The 3D optical profilometry technique was able to provide accurate qualitative and quantitative assessment of changes on the enamel surface after debonding. Clinical relevance: Morphological changes in the topography of dental surfaces, especially if related to enamel loss and roughness, are of considerable clinical importance. The quantitative evaluation method used herein enables a more comprehensive understanding of the effects of orthodontic bonding on teeth. © 2013 Springer-Verlag Berlin Heidelberg.11

Peginterferon Plus Ribavirin And Sustained Virological Response Rate In Hcv-related Advanced Fibrosis: A Real Life Study

Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5-9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p= 0.24). SVR rates according to Child-Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment. © 2013 .1814852Afdhal, N.H., The natural history of hepatitis C (2004) Semin Liver Dis, 24 (SUPPL. 2), pp. 3-8Fattovich, G., Giustina, G., Degos, F., (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients (1997) Gastroenterology, 112, pp. 463-472Veldt, B.J., Heathcote, E.J., Wedemeyer, H., Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis (2007) Ann Intern Med, 147, pp. 677-684Alves de Mattos, A., Zambam de Mattos, A., Treatment of HCV infection in patients with cirrhosis (2010) Ann Hepatol, 9 (SUPPL.), pp. 80-83Shiratori, Y., Ito, Y., Yokosuka, O., Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival (2005) Ann Intern Med, 142, pp. 105-114Bruno, S., Stroffolini, T., Colombo, M., Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study (2007) Hepatology, 45, pp. 579-587Miyake, Y., Iwasaki, Y., Yamamoto, K., Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C (2010) Int J Cancer, 127, pp. 989-996Manns, M.P., McHutchison, J.G., Gordon, S.C., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (2001) Lancet, 358, pp. 958-965Bruno, S., Shiffman, M.L., Roberts, S.K., Efficacy and safety of peginterferon alfa-2a (40kD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis (2010) Hepatology, 51, pp. 388-397Schalm, S.W., Weiland, O., Hansen, B.E., Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis (1999) Gastroenterology, 117, pp. 408-413Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis (2000) N Engl J Med, 343, pp. 1673-1680Camma, C., Giunta, M., Andreone, P., Craxi, A., Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach (2001) J Hepatol, 34, pp. 593-602Zhang, C.H., Xu, G.L., Jia, W.D., Li, J.S., Ma, J.L., Ge, Y.S., Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials (2011) Int J Cancer, 129, pp. 1254-1264Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L., Seeff, L.B., American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011) Hepatology, 54, pp. 1433-1444Craxì, A., Pawlotsky, J.M., Wedemeyer, H., EASL Clinical Practice Guidelines: management of hepatitis C virus infection (2011) J Hepatol, 55, pp. 245-264D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies (2006) J Hepatol, 44, pp. 217-231Poordad, F., McCone, J., Bacon, B.R., Boceprevir for untreated chronic HCV genotype 1 infection (2011) N Engl J Med, 364, pp. 1195-1206Bacon, B.R., Gordon, S.C., Lawitz, E., Boceprevir for previously treated chronic HCV genotype 1 infection (2011) N Engl J Med, 364, pp. 1207-1217Zeuzem, S., Andreone, P., Pol, S., Telaprevir for retreatment of HCV infection (2011) N Engl J Med, 364, pp. 2417-2428Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Telaprevir for previously untreated chronic hepatitis C virus infection (2011) N Engl J Med, 364, pp. 2405-2416Ferenci, P., Fried, M.W., Shiffman, M.L., Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin (2005) J Hepatol, 43, pp. 425-433de Segadas-Soares, J.A., Villela-Nogueira, C.A., Perez, R.M., Nabuco, L.C., Brandão-Mello, C.E., Coelho, H.S., Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin (2009) J Clin Gastroenterol, 43, pp. 362-366Giannini, E.G., Basso, M., Savarino, V., Picciotto, A., Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension (2009) J Intern Med, 266, pp. 537-546Hezode, C., Dorival, C., Zoulim, F., Safety of Telaprevir or Boceprevir in combination with Peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC) (2012) J Hepatol, 56, pp. S1-S2